Go Digit General Insurance Limited

Lot Size
1 Lot = 55 Qty
Min Investment
₹14960
Subscription
Undersubscribed
Listing Gain
33(Points)

IPO Details

Open Date
May 15, 2024
Close Date
May 17, 2024
Allotment Date
May 21, 2024
Allotment Date
May 21, 2024
Refund Initiation
May 22, 2024
Demat Transfer
May 22, 2024
Listing Date
May 23, 2024
Fresh Issue
1125
Offer For Sale
1489.65
Issue Price
₹258 to ₹272
Face Value
₹10
Issue Type
Fresh Issue
Total Issue Size
2614.65 CR
QIB + NII Quota
75 + 15%
Retail Quota
10%
Listing On
NSE & BSE
Registrar
Link Intime India Pvt Ltd
Check Allotment Status

Company Financial Rusult In Crore

PERIOD ASSET REVENUE PROFIT
31-Dec-2023 3619.95 130.83 129.02
31-Mar-2023 3346.75 39.19 35.54
31-Mar-2022 2919.01 -293.64 -295.85
31-Mar-2021 1874.80 -118.55 -122.76
DRHP DRAFT

About Go Digit General Insurance Limited

Incorporated in December 2016, Go Digit General Insurance Limited is an insurance provider offering motor insurance, health insurance, travel insurance, property insurance, marine insurance, liability insurance, and other insurance products, which customers can customize to meet their needs.

The company has currently launched a total of 74 active products across all its business lines.

As of December 31, 2023, the company had about 61,972 partners, including 58,532 POSPs and other agents.

As of December 31, 2023, the company had a distribution center in 24 states and union territories in India.

As of Dec 31, 2023, the company had 473 active bots to automate tasks for functions and partners.

As of December 31, 2023, the company currently operates 75 offices throughout India.

As of March 31, 2023 and December 31, 2023, the company had 3,333 and 3,957 employees, respectively.

 

Know before investing

Strength

Simple and tailored customer experience.

Efficient, scalable operating platform, focused on empowering Distribution Partners.

Risk

The company relies on motor vehicle insurance products for a substantial portion of its revenues and profitability.

Go Digit received cautions, warnings, and show-cause notices from the IRDAI on various regulatory prescriptions in the past.

 

DISCLAIMER: None of the financial information published herein should be construed as an offer to buy or sell securities or as advice in any way. All information published herein is for educational and informational purposes only and should not be relied upon as a basis for investment decisions under any circumstances. Readers must consult a qualified financial advisor before making any actual investment decisions based on the information published herein. Any reader who makes decisions based on the information published herein does so solely at his or her own risk. Investors should be aware that any investment in equity markets is subject to unpredictable market-related risks. The author does not intend to invest in this offering.